Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry

Area of Science:

• Biotechnology
• Molecular Biology
• Pharmacology

Background:

• The FDA approval of the first small interfering RNA (siRNA) drug, Patisiran, in 2018 heralded a new era for RNA interference (RNAi) therapeutics.
• MicroRNAs (miRNAs), crucial post-transcriptional gene regulators, are actively researched and in clinical trials.
• Both siRNA and miRNA mimics are approximately 21-nucleotide RNA duplexes that induce messenger RNA (mRNA) silencing.

Purpose of the Study:

• To compare small interfering RNA (siRNA) and microRNA (miRNA) mimics in the context of therapeutic development.
• To explore whether developed siRNA technology renders miRNA mimics unnecessary or if miRNA mimics offer distinct advantages.
• To identify key research areas for advancing miRNA mimic clinical applications.

Main Methods:

• Comprehensive comparison of siRNA and miRNA characteristics.
• Analysis of lessons learned from successful siRNA therapeutics.
• Evaluation of unique miRNA properties for therapeutic potential.

Main Results:

• siRNA and miRNA mimics share similarities as ~21 nucleotide RNA duplexes for mRNA silencing.
• miRNA mimics exhibit unique properties and advantages not fully replicable by siRNA.
• Endogenous nature of miRNAs allows for regulation and buffering of gene silencing effects, potentially mitigating off-target impacts.

Conclusions:

• miRNA mimics possess distinct therapeutic advantages over siRNA, making them a valuable class of drugs.
• Understanding the fundamental differences between siRNA and miRNA mimics is crucial for optimizing the development of miRNA mimic therapeutics.
• Further research into miRNA mimic characteristics will facilitate their successful clinical translation.